OpGen, Inc. Announces Timing for Third Quarter Financial Results and Conference Call

GAITHERSBURG, Md., Nov. 4, 2015 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), an early-stage commercial molecular testing and bioinformatics company, today announced that financial results for the company's third quarter ended September 30, 2015 will be released Thursday, November 12, 2015 following the close of market. The management team will host a conference call discussing the company's financial results and recent developments on Thursday, November 12, 2015 at 4:30 p.m. E.T. The call may be accessed by dialing (888) 883-4599 (domestic) or (484) 653-6821 (international) five minutes prior to the start of the call and providing passcode 63158584.

The live, listen-only webcast of the conference call may be accessed by visiting the investors section of the company's website at http://ir.opgen.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company's website.

A telephone replay also will be available from 7:30 p.m. E.T. through November 18, 2015 and may be accessed by dialing (855) 859-2056 from within the U.S. or (404) 537-3406 from outside the U.S. All listeners should provide passcode 63158584.

About OpGen

OpGen, Inc. is an early commercial-stage molecular testing and bioinformatics company focused on assisting healthcare providers to combat multidrug-resistant organism (MDRO) bacterial infections – "Superbugs." The Company is addressing this growing public health threat by rapidly delivering precise, actionable information to help identify, combat, and prevent the spread of these complex infections that jeopardize the safety of our hospitals and other long-term care facilities. OpGen offers a full portfolio of Acuitas® products including the MDRO Gene Test, the Resistome Test, microbial Whole Genome Sequence Analysis, Acuitas Lighthouse™ MDRO Management System and QuickFISH™, a suite of FDA-cleared and CE-marked diagnostics for rapid molecular testing of positive blood cultures designed to assure appropriate antibiotic therapy. Learn more at www.opgen.com

CONTACT: OpGen Michael Farmer Director, Marketing (240) 813-1284 mfarmer@opgen.com InvestorRelations@opgen.com Investors LHA Kim Sutton Golodetz (212) 838-3777 kgolodetz@lhai.com or Bruce Voss (310) 691-7100 bvoss@lhai.comSource:OpGen, Inc.